Safety of beta-agonists with different duration of action in patients with arterial hypertension and broncho-obstructive diseases

Objective. To examine the safety of beta-agonists (BA) with different duration of action in patients with arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD) or bronchial asthma (BA).Materials and methods: 40 patients (22 - male, 18 - female) with AH and COPD and AH and asthma aged 18 years were enrolled and examined initially. At the next three month, patients were treated with 3 types of BA: at the 1st month - with salbutamol (SABA), at the 2nd - with formoterol (LABA), at the 3rd - with indacaterol (ULABA). Initially, after one week and at the end of each month blood pressure (BP) and heart rate (HR) on the visit, oxygen saturation of peripheral blood, computer spirometry, serum potassium in blood, electrocardiogram, were evaluate. Initially, after one week and at the end of three month of treatment with SABA, LABA and ULABA all patients underwent holter monitoring and ambulatory blood pressure 24-monitoring.Results. Baseline, 1-month, 2-month, 3-month BP and HR levels on the visit were similar among all patients ( p =NS). At the end of the 3rd month of treatment with BA different duration of action in patients with AH and COPD daily average systolic BP (SBP) was lowered than initially ( p